Element closed its acquisition of Loop Genomics, a long-read solutions company. Financial terms were undisclosed; Loop founder and CEO Tuval Ben-Yehezkel joined Element as Senior Director of Applications.
SourcePublic company, workplace, funding, and market signals
Updated Aug 16, 2026
Element Biosciences is a privately held life-science technology company developing affordable, high-quality DNA sequencing and multiomics platforms. Its mission is to democratize access to advanced biological tools and accelerate research, translational science, and diagnostic development.
Primary product
The AVITI™ System family: benchtop DNA sequencing instruments based on Element’s proprietary Avidite Base Chemistry (ABC™), including AVITI, lower-throughput AVITI LT, and the multiomics-enabled AVITI24.
Founded
2017
Headquarters
10055 Barnes Canyon Road, Suite 100, San Diego, California 92121, United States
Team size
300-400
Work style
Hybrid
Industry
Biotechnology
Sub-industry
Genomics, next-generation sequencing, multiomics, and life-science research tools
Offices
Business model
Stage
Series E / late-stage growth; privately held
Total raised
$680M
Latest round
Series E · Jun 2026
Latest amount
$175M
Jun 2026 · Samsung Electronics; total round size and other investors undisclosed
Jul 2024 · Wellington Management
Jun 2021 · Janus Henderson Investors, Logos Capital, Meritech Capital, T. Rowe Price, and Morgan Stanley
Series B / additional financing
Jun 2020
Jan 2020 · Fidelity Investments and JS Capital
Jun 2019 · Foresite Capital and Venrock
Feb 2018 · U.S. Department of Health and Human Services
Leadership
CEO, Co-Founder, and Board Member
CTO and SVP of Advanced Research, Co-Founder
VP of Biochemistry and Co-Founder
Edwin Hauw
SVP of Marketing and Product Management
Yaron Hakak, PhD
SVP of Corporate and Business Development
Danae Van Oene
SVP of Global Sales and Support
Francisco Garcia, PhD
SVP of Informatics
Logan Zinser
SVP of Finance
Element describes its culture as collaborative, tenacious, authentic, and mission-driven, with scientists and engineers working to make advanced biological tools more accessible. The company emphasizes employee wellbeing, inclusion, customer focus, and rapid product innovation. Public job postings show a mix of onsite San Diego, hybrid, and territory-based remote roles rather than a single universal work arrangement.
Work style
Hybrid
Compensation
Public job postings provide salary ranges and commonly mention stock options, discretionary annual bonuses, no-cost health insurance, 401(k) matching, and flexible PTO. Example postings include $119,000-$156,000 base compensation for a San Diego enterprise-data role and approximately $97,000-$118,000 for a San Diego hybrid field-operations role. Sponsorship requirements vary by position and are not confirmed company-wide.
Benefits
Pricing
Instrument sales plus recurring reagent and consumables revenue, with volume discounts, leasing/financing options, and a throughput-based model. Publicly reported examples include approximately $289,000 for an AVITI instrument, $249,000 each in a three-or-more instrument bundle, an AVITI 150-cycle kit priced at $1,080 in 2022, and throughput pricing targeting as low as $200 per genome or $2 per gigabase subject to volume and contract terms. A 2023 throughput program was reported at $138,000 per quarter for up to 230 kits.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$50 million-$100 million annually; reported approximately $60 million for 2024, with management targeting $100 million for 2025
Estimated monthly visits
19.5K
Traffic estimate as of Jun 2026
Element closed its acquisition of Loop Genomics, a long-read solutions company. Financial terms were undisclosed; Loop founder and CEO Tuval Ben-Yehezkel joined Element as Senior Director of Applications.
SourceThe announced Series E financing was subject to regulatory approval, and the total round size and valuation were not disclosed. The disclosed financing included $175 million from Samsung Electronics.
SourceElement Biosciences · Jun 2026
Element announced an upsized Series E financing including $175 million from Samsung Electronics. The capital is intended to support commercialization, global expansion, and development of genomic, multiomic, and diagnostic products.
Element Biosciences · Oct 2025
Element and Twist launched an end-to-end workflow designed to move from sample to sequencer in as little as five hours, using on-flow-cell enrichment and Twist library-preparation products.
Element Biosciences · May 2025
The companies expanded their collaboration, with Twist becoming the exclusive provider of specified Trinity-compatible library-preparation and target-enrichment workflows for AVITI.
Element Biosciences · Apr 2025
Element announced accelerated availability and preorder plans for library-prep-free direct-in-sample sequencing on AVITI24, targeting applications including lineage tracing, CRISPR screens, targeted RNA sequencing, and custom protein analysis.
Business Wire · Jan 2025
Revvity and Element announced a strategic agreement to co-develop an in-vitro-diagnostic workflow for neonatal sequencing, supporting Element’s planned expansion of AVITI into regulated clinical applications.
15 jobs at Element Biosciences